EA201892217A1 - Т-КЛЕТОЧНЫЕ РЕЦЕПТОРЫ, КОТОРЫЕ РАСПОЗНАЮТ МУТАНТНЫЕ ВАРИАНТЫ СО СДВИГОМ РАМКИ СЧИТЫВАНИЯ TGFβRII - Google Patents
Т-КЛЕТОЧНЫЕ РЕЦЕПТОРЫ, КОТОРЫЕ РАСПОЗНАЮТ МУТАНТНЫЕ ВАРИАНТЫ СО СДВИГОМ РАМКИ СЧИТЫВАНИЯ TGFβRIIInfo
- Publication number
- EA201892217A1 EA201892217A1 EA201892217A EA201892217A EA201892217A1 EA 201892217 A1 EA201892217 A1 EA 201892217A1 EA 201892217 A EA201892217 A EA 201892217A EA 201892217 A EA201892217 A EA 201892217A EA 201892217 A1 EA201892217 A1 EA 201892217A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- chain domain
- seq
- reading frame
- tgfβrii
- present
- Prior art date
Links
- 108091008874 T cell receptors Proteins 0.000 title abstract 2
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 title 1
- 102100024952 Protein CBFA2T1 Human genes 0.000 abstract 5
- 230000009258 tissue cross reactivity Effects 0.000 abstract 4
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 3
- 102100033108 Transketolase-like protein 1 Human genes 0.000 abstract 2
- 239000012642 immune effector Substances 0.000 abstract 2
- 229940121354 immunomodulator Drugs 0.000 abstract 2
- 102000039446 nucleic acids Human genes 0.000 abstract 2
- 108020004707 nucleic acids Proteins 0.000 abstract 2
- 150000007523 nucleic acids Chemical class 0.000 abstract 2
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 abstract 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 abstract 1
- 102000043129 MHC class I family Human genes 0.000 abstract 1
- 108091054437 MHC class I family Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 238000007792 addition Methods 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000037430 deletion Effects 0.000 abstract 1
- 238000012217 deletion Methods 0.000 abstract 1
- 230000037433 frameshift Effects 0.000 abstract 1
- 230000035772 mutation Effects 0.000 abstract 1
- 238000011275 oncology therapy Methods 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 238000006467 substitution reaction Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/46443—Growth factors
- A61K39/464434—Transforming growth factor [TGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/46449—Melanoma antigens
- A61K39/464491—Melan-A/MART
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/495—Transforming growth factor [TGF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/50—Colon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Wood Science & Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- General Engineering & Computer Science (AREA)
- Hematology (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Настоящее изобретение относится к молекулам ТКР, которые распознают неопептиды, вырабатываемые в результате связанной с раком мутации со сдвигом рамки считывания "-1A" в TGFβRII человека. Молекулы ТКР способны связывать пептид, содержащий последовательность SEQ ID NO: 1, причем указанный пептид представлен ГКГС класса I и содержит домен α-цепи и домен β-цепи, где каждый домен цепи содержит три последовательности CDR, причем a) CDR 1, 2 и 3 из домена α-цепи содержат последовательности SEQ ID NO: 2, 3 и 4 соответственно; и b) CDR 1, 2 и 3 из домена β-цепи содержат последовательности SEQ ID NO: 5, 6 и 7 соответственно, и при этом одна или более из указанных последовательностей CDR необязательно могут быть модифицированы путем замены, добавления или делеции 1 или 2 аминокислот. Настоящее изобретение относится к молекулам нуклеиновых кислот, кодирующим такие ТКР, а также к растворимым молекулам ТКР, содержащим указанные последовательности CDR. Молекулы нуклеиновых кислот согласно настоящему изобретению можно применять для модификации иммунных эффекторных клеток для экспрессии ТКР, как определено в настоящем документе, и такие модифицированные иммунные эффекторные клетки, а также растворимые ТКР, определенные выше, можно применять в терапии рака.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1608052.5A GB201608052D0 (en) | 2016-05-09 | 2016-05-09 | T-cell receptors which recognise frameshift mutants of TGF-beta RII |
| PCT/EP2017/061087 WO2017194555A1 (en) | 2016-05-09 | 2017-05-09 | T-CELL RECEPTORS WHICH RECOGNISE FRAMESHIFT MUTANTS OF TGFßRII |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA201892217A1 true EA201892217A1 (ru) | 2019-08-30 |
Family
ID=56297359
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201892217A EA201892217A1 (ru) | 2016-05-09 | 2017-05-09 | Т-КЛЕТОЧНЫЕ РЕЦЕПТОРЫ, КОТОРЫЕ РАСПОЗНАЮТ МУТАНТНЫЕ ВАРИАНТЫ СО СДВИГОМ РАМКИ СЧИТЫВАНИЯ TGFβRII |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20190336529A1 (ru) |
| EP (1) | EP3455249B1 (ru) |
| JP (1) | JP2019517790A (ru) |
| KR (1) | KR20190016507A (ru) |
| CN (1) | CN109328196B (ru) |
| AU (1) | AU2017261684A1 (ru) |
| CA (1) | CA3024555A1 (ru) |
| EA (1) | EA201892217A1 (ru) |
| GB (1) | GB201608052D0 (ru) |
| IL (1) | IL262873A (ru) |
| MX (1) | MX2018013581A (ru) |
| SG (1) | SG11201809716VA (ru) |
| WO (1) | WO2017194555A1 (ru) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10724043B2 (en) * | 2016-10-06 | 2020-07-28 | Nantbio, Inc. | Multi-pulse transfection methods and cells |
| WO2018104473A1 (en) | 2016-12-07 | 2018-06-14 | Oslo Universitetssykehus Hf | Compositions and methods for cell therapy |
| GB201713078D0 (en) * | 2017-08-15 | 2017-09-27 | Adaptimmune Ltd | T Cell Modification |
| JP2021500875A (ja) | 2017-10-06 | 2021-01-14 | オスロ ウニヴェルスィテーツスィーケフース ハーエフＯｓｌｏ Ｕｎｉｖｅｒｓｉｔｅｔｓｓｙｋｅｈｕｓ Ｈｆ | キメラ抗原受容体 |
| WO2020057619A1 (zh) * | 2018-09-21 | 2020-03-26 | 广东香雪精准医疗技术有限公司 | 一种识别afp抗原的高亲和力t细胞受体 |
| WO2020201527A1 (en) * | 2019-04-04 | 2020-10-08 | Umc Utrecht Holding B.V. | Modified immune receptor constructs |
| GB201907663D0 (en) | 2019-05-30 | 2019-07-17 | Ab Mavatar | Method for diagnosing colorectal cancer |
| WO2023050063A1 (zh) * | 2021-09-28 | 2023-04-06 | 溧阳瑅赛生物医药有限公司 | 一种识别hla-a*02:01/e629-38的tcr及其应用 |
| WO2024050399A1 (en) | 2022-09-01 | 2024-03-07 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Single domain antibodies targeting hpv e6/e7 oncogenic peptide/mhc complexes |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NO315238B1 (no) * | 1998-05-08 | 2003-08-04 | Gemvax As | Peptider som stammer fra leserammeforskyvingsmutasjoner i TBF<beta>II- eller BAX-genet, og farmasöytiske sammensetninger inneholdende disse,nukleinsyresekvenser som koder for slike peptider, plasmider og virusvektoreromfattende slikenukleinsy |
| FR2779432A1 (fr) * | 1998-06-08 | 1999-12-03 | Transgene Sa | Sequence nucleique du recepteur rii du tgfb, peptide code, et utilisations |
| US9109031B2 (en) * | 2009-07-29 | 2015-08-18 | Glaxo Group Limited | Ligands that bind TGF-β receptor RII |
| KR102395736B1 (ko) * | 2011-06-03 | 2022-05-06 | 조마 테크놀로지 리미티드 | Tgf-베타에 특이적인 항체 |
| JP6548579B2 (ja) * | 2012-12-06 | 2019-07-24 | ヴィクトリア リンク リミテッド | コンジュゲート化合物 |
| WO2015169853A1 (en) * | 2014-05-06 | 2015-11-12 | Universitetet I Oslo | Engineered invariant chain molecule for improved mhc class i loading |
| US20170106066A1 (en) * | 2014-06-10 | 2017-04-20 | Universitetet I Oslo | Engineered invariant chain molecule for improved mhc class i loading |
-
2016
- 2016-05-09 GB GBGB1608052.5A patent/GB201608052D0/en not_active Ceased
-
2017
- 2017-05-09 MX MX2018013581A patent/MX2018013581A/es unknown
- 2017-05-09 WO PCT/EP2017/061087 patent/WO2017194555A1/en active Application Filing
- 2017-05-09 SG SG11201809716VA patent/SG11201809716VA/en unknown
- 2017-05-09 CA CA3024555A patent/CA3024555A1/en active Pending
- 2017-05-09 AU AU2017261684A patent/AU2017261684A1/en not_active Abandoned
- 2017-05-09 CN CN201780038176.8A patent/CN109328196B/zh active Active
- 2017-05-09 JP JP2018559282A patent/JP2019517790A/ja active Pending
- 2017-05-09 EP EP17725537.9A patent/EP3455249B1/en active Active
- 2017-05-09 KR KR1020187035676A patent/KR20190016507A/ko active IP Right Grant
- 2017-05-09 US US16/099,329 patent/US20190336529A1/en not_active Abandoned
- 2017-05-09 EA EA201892217A patent/EA201892217A1/ru unknown
-
2018
- 2018-11-07 IL IL262873A patent/IL262873A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2017261684A1 (en) | 2018-12-13 |
| GB201608052D0 (en) | 2016-06-22 |
| KR20190016507A (ko) | 2019-02-18 |
| IL262873A (en) | 2019-01-31 |
| US20190336529A1 (en) | 2019-11-07 |
| WO2017194555A1 (en) | 2017-11-16 |
| EP3455249A1 (en) | 2019-03-20 |
| MX2018013581A (es) | 2019-07-04 |
| CN109328196B (zh) | 2022-11-01 |
| CN109328196A (zh) | 2019-02-12 |
| JP2019517790A (ja) | 2019-06-27 |
| CA3024555A1 (en) | 2017-11-16 |
| SG11201809716VA (en) | 2018-11-29 |
| EP3455249B1 (en) | 2023-05-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201892217A1 (ru) | Т-КЛЕТОЧНЫЕ РЕЦЕПТОРЫ, КОТОРЫЕ РАСПОЗНАЮТ МУТАНТНЫЕ ВАРИАНТЫ СО СДВИГОМ РАМКИ СЧИТЫВАНИЯ TGFβRII | |
| CY1124664T1 (el) | Υποδοχεις τ λεμφοκυτταρων | |
| CY1122729T1 (el) | Συμπλοκο παραγοντα viii με χτεν και πρωτεϊνη παραγοντα von willebrand, και χρησεις αυτου | |
| CY1122627T1 (el) | Αντισωματα εναντι της ceacam6 και χρησεις αυτων | |
| CY1118979T1 (el) | Αντισωματα που κατευθυνονται εναντι her-3 και χρησεις αυτων | |
| EA202091710A1 (ru) | Антитела против cd73 и способы их применения | |
| CY1123609T1 (el) | Βελτιστοποιηση αντισωματων που δεσμευουν το γονιδιο-3 ενεργοποιησης λεμφοκυτταρων (lag-3), και χρησεις εξ΄ αυτων | |
| CY1119647T1 (el) | Αντισωματα προσδεσης αλβουμινης και τμηματα προσδεσης αυτων | |
| PH12016500272A1 (en) | T cell receptors | |
| EA202091335A1 (ru) | Ограниченные hla класса i t-клеточные рецепторы против мутантного ras | |
| RU2022103870A (ru) | Модифицированный иммунорегуляторный элемент и изменение иммунитета посредством этого элемента | |
| EA201991696A1 (ru) | Т-клеточные рецепторы, связывающиеся с ny-eso-1, и способы их применения | |
| JP2019517790A5 (ru) | ||
| RU2016124280A (ru) | Клетка | |
| DK1765860T3 (da) | Ny-ESO-T.cellereceptor med höj affinitet | |
| RU2014148136A (ru) | Композиции т-клеток с недостаточностью рецепторов т-клеток | |
| BR112022001923A2 (pt) | Proteína de ligação ao antígeno, ácido nucleico isolado, célula hospedeira recombinante, composição farmacêutica, método de produção da proteína de ligação ao antígeno | |
| EA201000207A1 (ru) | Новые иммуногенные эпитопы для иммунотерапии | |
| MX2021009274A (es) | Moleculas de union a multiples dominios. | |
| CY1123997T1 (el) | Νεα μεταλλακτικη παραλλαγη αλβουμινης ανθρωπινου ορου | |
| EP4269562A3 (en) | Antigen binding molecules and methods of use thereof | |
| GB2543713A (en) | Polymeric proteins and uses thereof | |
| EA201390811A1 (ru) | Пептиды tomm34 и содержащие их вакцины | |
| EA202192252A1 (ru) | Высокоавидные т-клеточные рецепторы к wt1 и их применения | |
| EA201590927A1 (ru) | Пептиды |